Paeoniflorin and inflammation: promising mechanisms, little clinical evidence

A review of mechanisms, not an efficacy trial

Paeoniflorin is a monoterpene glycoside derived from the roots of plants in the genus Paeonia. The publication combines a review of the literature available in PubMed through 2025 with a network pharmacology analysis, which maps possible interactions between the molecule and various biological targets.

The dossier provides access only to the PubMed abstract, not the full text. This abstract specifies neither the number of included studies nor their sample sizes, comparators or durations. It therefore does not allow a precise assessment of the strength of each finding.

Several inflammatory pathways involved

According to the abstract, the collected studies suggest that paeoniflorin may modulate several pathways involved in inflammation, including TLR4/MyD88, NF-κB, MAPK and the NLRP3 inflammasome. They also describe a reduction in certain inflammatory mediators, including TNF-α, IL-1β and IL-6, as well as effects on oxidative stress and mitochondrial function.

These observations provide a biological basis for further research. On their own, they do not demonstrate reduced symptoms or improved health in a person taking this molecule. The targets proposed by computational mapping also require experimental confirmation.

Translation to humans remains to be demonstrated

The review reports preclinical potential in osteoarthritis, colitis and atherosclerosis, while highlighting the lack of clinical data. The abstract provides no numerical results that would allow a benefit in humans with these diseases to be estimated.

Another limitation is its low oral bioavailability: administering the molecule by this route does not guarantee sufficient exposure in the body. The authors propose improving its delivery and conducting rigorous clinical trials. These are avenues for research, not already validated solutions.

Reported low toxicity is not enough to establish safety

The abstract describes low toxicity but does not detail the conditions under which it was assessed. This wording does not establish the safety of a commercial supplement, particularly when taken alongside other treatments.

Interactions, contraindications, product quality and regulatory status in France or the European Union are not documented in the dossier. Funding and conflicts of interest could not be verified either.

What we can take away

This review supports further research into paeoniflorin. It is not sufficient to justify its use as a supplement against inflammation.